Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
复制标题
DOI：
10.1038/nrc1323
复制
发表时间：
2004-04-01
影响因子：
78.5
通讯作者：
Dalgleish, AG
中科院分区：
文献类型：
--
作者：
Bartlett, JB;Dredge, K;Dalgleish, AG
沙利度胺最初用于治疗晨吐，但在20世纪60年代因导致严重的先天性出生缺陷而被禁用。值得注意的是，沙利度胺随后被发现具有抗炎和抗血管生成的特性，并被确定为治疗多发性骨髓瘤的有效药物。通过对沙利度胺进行化学修饰而产生的一系列免疫调节药物已经被开发出来，以克服最初的破坏性副作用。它们强大的抗癌性能意味着这些药物现在正从沙利度胺的阴影中脱颖而出，成为有用的抗癌剂。
Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects. Remarkably, thalidomide was subsequently discovered to have anti-inflammatory and anti-angiogenic properties, and was identified as an effective treatment for multiple myeloma. A series of immunomodulatory drugs - created by chemical modification of thalidomide - have been developed to overcome the original devastating side effects. Their powerful anticancer properties mean that these drugs are now emerging from thalidomide's shadow as useful anticancer agents.